Cereno Scientific AB

The Chronic Pulmonary Hypertension market is projected to grow significantly by 2034, driven by increased awareness, improved diagnostics, and emerging therapies. Key companies include Bayer, Attgeno AB, and others, with treatments like ADEMPAS and CS1. The US leads in market size and cases, with Germany and Japan following. Emerging therapies promise to revolutionize treatment dynamics.